BacKgroUND: The aim of our study is to develop a clinical nomogram including metabolic syndrome status for the prediction of high-grade prostate cancer (Hg Pca). MeTHoDS: a series of men at increased risk of Pca undergoing prostate biopsies were enrolled in a single center. Demographic and clinical characteristics of the patients were recorded. Metabolic syndrome was defined according to the adult treatment panel iii. a nomogram was generated based on the logistic regression model and used to predict high grade prostate cancer defined as grade group ≥3 (ISUP 2014). ROC curves, calibration plots and decision curve analysis were used to evaluate the performance of the nomogram. RESULTS: Overall, 738 patients were enrolled. Greater than or equal to 294/738 (40%) of the patients presented PCa and of those patients, 84/294 (39%) presented high grade disease (Grade Group ≥3). On multivariate analysis, DRE (OR: 3.24, 95% CI: 1.80-5.84), PSA (OR: 1.10, 95% CI: 1.05-1.16), PV (OR: 0.98, 95% CI: 0.97-0.99) and MetS (OR: 2.02, 95% CI: 1.13-3.59) were predictors of HG PCa. The nomogram based on the model presented good discrimination (AUC: 0.76), good calibration (Hosmer-Lemeshow Test, P>0.05) and a net benefit in the range of probabilities between 10% and 70%. coNclUSioNS: Metabolic syndrome is highly prevalent in patients at risk of prostate cancer and is particularly associated with high-grade prostate cancer. our nomogram offers the possibility to include metabolic status in the assessment of patients at risk of prostate cancer to identify men who may have a high-grade form of the disease. external validation is warranted before its clinical implementation.

The role of metabolic syndrome in high grade prostate cancer: development of a clinical nomogram / de Nunzio, C.; Tema, G.; Lombardo, R.; Cicione, A.; Dell'Oglio, P.; Tubaro, A.. - In: MINERVA UROLOGICA E NEFROLOGICA. - ISSN 0393-2249. - 72:6(2020), pp. 729-736. [10.23736/S0393-2249.20.03797-2]

The role of metabolic syndrome in high grade prostate cancer: development of a clinical nomogram

de Nunzio C.;Tema G.;Lombardo R.;Cicione A.;Tubaro A.
2020

Abstract

BacKgroUND: The aim of our study is to develop a clinical nomogram including metabolic syndrome status for the prediction of high-grade prostate cancer (Hg Pca). MeTHoDS: a series of men at increased risk of Pca undergoing prostate biopsies were enrolled in a single center. Demographic and clinical characteristics of the patients were recorded. Metabolic syndrome was defined according to the adult treatment panel iii. a nomogram was generated based on the logistic regression model and used to predict high grade prostate cancer defined as grade group ≥3 (ISUP 2014). ROC curves, calibration plots and decision curve analysis were used to evaluate the performance of the nomogram. RESULTS: Overall, 738 patients were enrolled. Greater than or equal to 294/738 (40%) of the patients presented PCa and of those patients, 84/294 (39%) presented high grade disease (Grade Group ≥3). On multivariate analysis, DRE (OR: 3.24, 95% CI: 1.80-5.84), PSA (OR: 1.10, 95% CI: 1.05-1.16), PV (OR: 0.98, 95% CI: 0.97-0.99) and MetS (OR: 2.02, 95% CI: 1.13-3.59) were predictors of HG PCa. The nomogram based on the model presented good discrimination (AUC: 0.76), good calibration (Hosmer-Lemeshow Test, P>0.05) and a net benefit in the range of probabilities between 10% and 70%. coNclUSioNS: Metabolic syndrome is highly prevalent in patients at risk of prostate cancer and is particularly associated with high-grade prostate cancer. our nomogram offers the possibility to include metabolic status in the assessment of patients at risk of prostate cancer to identify men who may have a high-grade form of the disease. external validation is warranted before its clinical implementation.
2020
metabolic syndrome; nomograms; prostatic neopalsms
01 Pubblicazione su rivista::01a Articolo in rivista
The role of metabolic syndrome in high grade prostate cancer: development of a clinical nomogram / de Nunzio, C.; Tema, G.; Lombardo, R.; Cicione, A.; Dell'Oglio, P.; Tubaro, A.. - In: MINERVA UROLOGICA E NEFROLOGICA. - ISSN 0393-2249. - 72:6(2020), pp. 729-736. [10.23736/S0393-2249.20.03797-2]
File allegati a questo prodotto
File Dimensione Formato  
DeNunzio_The-role_2020.pdf

solo gestori archivio

Tipologia: Documento in Post-print (versione successiva alla peer review e accettata per la pubblicazione)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 680.44 kB
Formato Adobe PDF
680.44 kB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1506259
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 5
  • ???jsp.display-item.citation.isi??? 5
social impact